Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) declared a quarterly dividend on Tuesday, May 20th, investing.com reports. Investors of record on Thursday, May 22nd will be given a dividend of 0.43 per share on Monday, June 30th. This represents a $1.72 dividend on an annualized basis and a yield of 13.95%. The ex-dividend date of this dividend is Thursday, May 22nd.
Abrdn Life Sciences Investors Stock Performance
NYSE:HQL traded up $0.16 during midday trading on Friday, reaching $12.33. The stock had a trading volume of 67,599 shares, compared to its average volume of 105,266. Abrdn Life Sciences Investors has a 1-year low of $10.55 and a 1-year high of $15.90. The firm's fifty day simple moving average is $12.24 and its 200-day simple moving average is $13.26.
Insider Activity at Abrdn Life Sciences Investors
In related news, major shareholder Saba Capital Management, L.P. sold 32,922 shares of the firm's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $13.01, for a total value of $428,315.22. Following the transaction, the insider now directly owns 3,240,630 shares in the company, valued at approximately $42,160,596.30. This trade represents a 1.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last three months, insiders have sold 210,280 shares of company stock worth $2,567,789. 10.06% of the stock is owned by insiders.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Abrdn Life Sciences Investors stock. Royal Bank of Canada raised its stake in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 53.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 73,475 shares of the company's stock after purchasing an additional 25,542 shares during the period. Royal Bank of Canada owned approximately 0.25% of Abrdn Life Sciences Investors worth $934,000 as of its most recent SEC filing. 32.21% of the stock is owned by institutional investors.
About Abrdn Life Sciences Investors
(
Get Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
See Also
Before you consider abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and abrdn Life Sciences Investors wasn't on the list.
While abrdn Life Sciences Investors currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
